JP2015522522A - 刺激に誘発される薬物再発の阻止 - Google Patents

刺激に誘発される薬物再発の阻止 Download PDF

Info

Publication number
JP2015522522A
JP2015522522A JP2015503431A JP2015503431A JP2015522522A JP 2015522522 A JP2015522522 A JP 2015522522A JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015522522 A JP2015522522 A JP 2015522522A
Authority
JP
Japan
Prior art keywords
ethoxycarbonyl
drug
laurate
hydroxymethyl
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522522A5 (enExample
Inventor
グリック，スタンレー，ディー．
ポルストン，ジェイムズ，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015522522A publication Critical patent/JP2015522522A/ja
Publication of JP2015522522A5 publication Critical patent/JP2015522522A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015503431A 2012-03-27 2013-03-25 刺激に誘発される薬物再発の阻止 Pending JP2015522522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615953P 2012-03-27 2012-03-27
US61/615,953 2012-03-27
PCT/US2013/033703 WO2013148572A1 (en) 2012-03-27 2013-03-25 Blocking of cue-induced drug reinstatement

Publications (2)

Publication Number Publication Date
JP2015522522A true JP2015522522A (ja) 2015-08-06
JP2015522522A5 JP2015522522A5 (enExample) 2016-05-19

Family

ID=49261147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015503431A Pending JP2015522522A (ja) 2012-03-27 2013-03-25 刺激に誘発される薬物再発の阻止

Country Status (6)

Country Link
US (1) US20150051192A1 (enExample)
EP (1) EP2830601A4 (enExample)
JP (1) JP2015522522A (enExample)
AU (1) AU2013239995A1 (enExample)
CA (1) CA2908240A1 (enExample)
WO (1) WO2013148572A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508979A (ja) * 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CA2806232A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US20150258110A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence using ibogaine
WO2015163844A1 (en) * 2014-04-21 2015-10-29 Demerx, Inc. N-substituted noribogaine prodrugs
AU2020357951B2 (en) * 2019-10-01 2024-01-11 Mind Medicine, Inc. 18-MC for treatment of substance use disorders
WO2023278108A1 (en) * 2021-06-29 2023-01-05 Mind Medicine, Inc. 18-mc for treating obesity
WO2025117491A1 (en) * 2023-12-01 2025-06-05 Kuleon Llc Azepino analogs and methods of making and using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211360B1 (en) * 1995-08-08 2001-04-03 Albany Medical College Ibogamine congeners
US20020103109A1 (en) * 2001-01-29 2002-08-01 Glick Stanley D. Methods and compositions for treating addiction disorders
US20060035889A1 (en) * 2004-08-13 2006-02-16 Tedford Clark E Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
WO2010105103A1 (en) * 2009-03-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
EA200970369A1 (ru) * 2006-10-09 2009-08-28 Смитклайн Бичам Корпорейшн Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака
US8785472B2 (en) * 2010-05-11 2014-07-22 National Cheng Kung University Use of dextromethorphan in treating addictive behavior or bipolar disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211360B1 (en) * 1995-08-08 2001-04-03 Albany Medical College Ibogamine congeners
US20020103109A1 (en) * 2001-01-29 2002-08-01 Glick Stanley D. Methods and compositions for treating addiction disorders
US20060035889A1 (en) * 2004-08-13 2006-02-16 Tedford Clark E Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
WO2010105103A1 (en) * 2009-03-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GLICK S D, NEUROPSYCHOPHARMACOLOGY, vol. vol.35, Puppl.1, JPN6017001838, 2010, pages 14, ISSN: 0003698897 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508979A (ja) * 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine

Also Published As

Publication number Publication date
CA2908240A1 (en) 2013-10-03
AU2013239995A1 (en) 2014-11-06
WO2013148572A1 (en) 2013-10-03
EP2830601A1 (en) 2015-02-04
US20150051192A1 (en) 2015-02-19
EP2830601A4 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
JP2015522522A (ja) 刺激に誘発される薬物再発の阻止
Stefanski et al. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine
Park et al. Cocaine administered into the medial prefrontal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens
Olausson et al. Repeated nicotine exposure enhances responding with conditioned reinforcement
Xi et al. Selective dopamine D3 receptor antagonism by SB‐277011A attenuates cocaine reinforcement as assessed by progressive‐ratio and variable‐cost–variable‐payoff fixed‐ratio cocaine self‐administration in rats
Tuerke et al. Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT3 receptor in the posterior and anterior insular cortex
Rezvani et al. Effects of sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats
Papale et al. Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors
Gamberino et al. Neurobiology of tobacco smoking and other addictive disorders
Popik et al. Mesolimbic NMDA receptors are implicated in the expression of conditioned morphine reward
Brennan et al. Tobacco particulate matter self‐administration in rats: differential effects of tobacco type
JP2002532393A (ja) エキソ−ｒ−メカミラミン製剤および治療におけるその使用
Eisenberg et al. The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats
Huang et al. Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens
Silver et al. Mecamylamine in Tourette's syndrome: a two-year retrospective case study
Liu et al. Effects of dopamine antagonists on drug cue-induced reinstatement of nicotine-seeking behavior in rats
Xi et al. Mechanism-based medication development for the treatment of nicotine dependence
Harmer et al. Repeated d-amphetamine enhances stimulated mesoamygdaloid dopamine transmission
Stefanski et al. Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration
Harris et al. β-adrenergic antagonism alters the behavioral and neurochemical responses to cocaine
Glover et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers
WO2008154015A1 (en) Cb1 receptor antagonists and uses thereof
Batman et al. Attenuation of nicotine’s discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A/2C receptor agonists
Goodman et al. Hippocampus NMDA receptors selectively mediate latent extinction of place learning
Jang et al. Attenuation of morphine tolerance and withdrawal syndrome by coadministration of nalbuphine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180710